欧盟HMA药品数据库（European Union HMA Authorisation of Medicines DataBase）
MR编号CZ/H/0801/002
药品名称Octreotide Teva
活性成分
    • octreotide acetate 20.0 mg
剂型Powder and solvent for suspension for injection
上市许可持有人Teva B.V. Swensweg 5, Haarlem 2031GA Netherlands
参考成员国 - 产品名称Czechia (CZ)
OCTREOTIDE TEVA
互认成员国 - 产品名称
    • Denmark (DK)
    • Belgium (BE)
      Octreoteva Long Acting 20 mg poeder en oplosmiddel voor suspensie voor injectie met verlengde afgifte
    • Netherlands (NL)
    • Luxembourg (LU)
    • Iceland (IS)
      Octreoanne 20 mg stungulyfsstofn og leysir, forðadreifa
    • United Kingdom (Northern Ireland) (XI)
      Octreotide LAI Teva
    • Ireland (IE)
    • Austria (AT)
    • France (FR)
    • Spain (ES)
    • Portugal (PT)
    • Italy (IT)
    • Sweden (SE)
    • Norway (NO)
      Octreoanne
    • Finland (FI)
    • Poland (PL)
      Okteva
    • Latvia (LV)
      Octreotide Teva 20 mg pulveris un šķīdinātājs ilgstošas darbības injekciju suspensijas pagatavošanai
    • Lithuania (LT)
      Octreotide Teva 20 mg milteliai ir tirpiklis pailginto atpalaidavimo injekcinei suspensijai
    • Estonia (EE)
      OCTREOTIDE TEVA
    • Hungary (HU)
      OKTREOTID TEVA 20 mg por és oldószer retard szuszpenziós injekcióhoz
    • Bulgaria (BG)
      Octreotide LAI Teva
    • Romania (RO)
    • Slovakia (SK)
      Oktreotid Teva 20 mg
    • Slovenia (SI)
    • Croatia (HR)
      Oktreotid Teva 20 mg prašak i otapalo za suspenziju za injekciju s produljenim oslobađanjem
许可日期2019/04/16
最近更新日期2024/03/21
药物ATC编码
    • H01CB02 octreotide
申请类型
  • TypeLevel1：Known Active Substance
  • TypeLevel2：Initial Application
  • TypeLevel3：Generic Art 10.1 and 10.2 Dir 2001/83/EC
  • TypeLevel4：Chemical Substance
  • TypeLevel5：Prescription Only
附件文件下载
市场状态Positive
©2006-2024 Drugfuture->European Union HMA Authorisation of Medicines DataBase